Crizotinib in ROS1-rearranged non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins
  • Pyrazoles
  • Pyridines

abstract

  • In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which crizotinib is highly active. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4264527

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1406766

PubMed ID

  • 25264305

Additional Document Info

start page

  • 1963

end page

  • 71

volume

  • 371

number

  • 21